This report focuses on the global Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy development in United States, Europe and China.
Gene therapy is an experimental treatment that involves introducing genetic material into a persons cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a vector. The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
Gene therapy is a method that involves introducing genetic material into a persons cells to fight or prevent diseases. In recent decades of years, researchers are paying more and more attention on it. Until today, it is still in infancy. There are many bio-technology companies entered into this market and carry on related research and development.
These research companies are including Bluebird Bio, Sangamom, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical and Advantagene. Among them, the top 5 research companies occupied more than 85% market.
Generally, the research fees of companies are come from their collaboration partners. For example, Bayer Healthcare is the partner of Dimension Therapeutics. General, some products of these companies are in the period 3 of their pipeline.
In general, cancer diseases are still the largest application with market share over 65% in 2015. In addition, there are some companies are focus on rare diseases.
In 2017, the global Gene Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
The key players covered in this study
Bluebird Bio
Sangamo
Spark Therapeutics
Dimension Therapeutics
Avalanche Bio
Celladon
Vical Inc.
Advantagene
Market segment by Type, the product can be split into
Ex vivo
In Vivo
Market segment by Application, split into
Cancer
Monogenic
Infectious disease
Cardiovascular disease
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Gene Therapy status, future forecast, growth opportunity, key market and key players.
To present the Gene Therapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Gene Therapy are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Gene Therapy Market, By Indication
7.1. Gene Therapy Market, By Indication Type, 2020-2030
7.1.1. Acute Lymphoblastic Leukemia (ALL)
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Inherited Retinal Disease
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Large B-cell Lymphoma
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. ADA-SCID
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Melanoma (lesions)
7.1.5.1. Market Revenue and Forecast (2016-2030)
7.1.6. Beta-Thalassemia Major/SCD
7.1.6.1. Market Revenue and Forecast (2016-2030)
7.1.7. Head & Neck Squamous Cell Carcinoma
7.1.7.1. Market Revenue and Forecast (2016-2030)
7.1.8. Peripheral Arterial Disease
7.1.8.1. Market Revenue and Forecast (2016-2030)
7.1.9. Spinal Muscular Atrophy (SMA)
7.1.9.1. Market Revenue and Forecast (2016-2030)
7.1.10. Others
7.1.10.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Gene Therapy Market, By Vector Type
8.1. Gene Therapy Market, By Vector Type, 2020-2030
8.1.1. Lentivirus
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. AAV
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Retrovirus & gamma Retrovirus
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Modified Herpes Simplex Virus
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Adenovirus
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Non-viral Plasmid Vector
8.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Gene Therapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.1.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.2.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.3.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Indication (2016-2030)
9.4.6.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.3.2. Market Revenue and Forecast, By Vector Type (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Indication (2016-2030)
9.5.4.2. Market Revenue and Forecast, By Vector Type (2016-2030)
Chapter 10. Company Profiles
10.1. REGENXBIO, Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Oxford BioMedica plc
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Dimension Therapeutics, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bristol-Myers Squibb Company
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. SANOFI
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Applied Genetic Technologies Corporation
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. F. Hoffmann-La Roche Ltd.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Bluebird Bio, Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Novartis AG
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
10.11. UniQure N.V.
10.11.1. Company Overview
10.11.2. Product Offerings
10.11.3. Financial Performance
10.11.4. Recent Initiatives
10.12. Shire Plc
10.12.1. Company Overview
10.12.2. Product Offerings
10.12.3. Financial Performance
10.12.4. Recent Initiatives
10.13. Cellectis S.A.
10.13.1. Company Overview
10.13.2. Product Offerings
10.13.3. Financial Performance
10.13.4. Recent Initiatives
10.14. Sangamo Therapeutics, Inc.
10.14.1. Company Overview
10.14.2. Product Offerings
10.14.3. Financial Performance
10.14.4. Recent Initiatives
10.15. Orchard Therapeutics
10.15.1. Company Overview
10.15.2. Product Offerings
10.15.3. Financial Performance
10.15.4. Recent Initiatives
10.16. Gilead Lifesciences, Inc.
10.16.1. Company Overview
10.16.2. Product Offerings
10.16.3. Financial Performance
10.16.4. Recent Initiatives
10.17. Benitec Biopharma Ltd.
10.17.1. Company Overview
10.17.2. Product Offerings
10.17.3. Financial Performance
10.17.4. Recent Initiatives
10.18. Sibiono GeneTech Co., Ltd.
10.18.1. Company Overview
10.18.2. Product Offerings
10.18.3. Financial Performance
10.18.4. Recent Initiatives
10.19. Shanghai Sunway Biotech Co., Ltd.
10.19.1. Company Overview
10.19.2. Product Offerings
10.19.3. Financial Performance
10.19.4. Recent Initiatives
10.20. Gensight Biologics S.A.
10.20.1. Company Overview
10.20.2. Product Offerings
10.20.3. Financial Performance
10.20.4. Recent Initiatives
10.21. Transgene
10.21.1. Company Overview
10.21.2. Product Offerings
10.21.3. Financial Performance
10.21.4. Recent Initiatives
10.22. Calimmune, Inc.
10.22.1. Company Overview
10.22.2. Product Offerings
10.22.3. Financial Performance
10.22.4. Recent Initiatives
10.23. Epeius Biotechnologies Corp.
10.23.1. Company Overview
10.23.2. Product Offerings
10.23.3. Financial Performance
10.23.4. Recent Initiatives
10.24. Astellas Pharma, Inc.
10.24.1. Company Overview
10.24.2. Product Offerings
10.24.3. Financial Performance
10.24.4. Recent Initiatives
10.25. American Gene Technologies
10.25.1. Company Overview
10.25.2. Product Offerings
10.25.3. Financial Performance
10.25.4. Recent Initiatives
10.26. BioMarin Pharmaceuticals, Inc.
10.26.1. Company Overview
10.26.2. Product Offerings
10.26.3. Financial Performance
10.26.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers